These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2327116)

  • 41. Pharmacokinetics and bioavailability of digoxin capsules, solution and tablets after single and multiple doses.
    Lloyd BL; Greenblatt DJ; Allen MD; Harmatz JS; Smith TW
    Am J Cardiol; 1978 Jul; 42(1):129-36. PubMed ID: 677028
    [No Abstract]   [Full Text] [Related]  

  • 42. Digoxin solution in capsules (Lanoxicaps).
    Med Lett Drugs Ther; 1983 Dec; 25(650):111-2. PubMed ID: 6656690
    [No Abstract]   [Full Text] [Related]  

  • 43. Effect of a standard breakfast on digoxin absorption in normal subjects.
    Johnson BF; O'Grady J; Sabey GA; Bye C
    Clin Pharmacol Ther; 1978 Mar; 23(3):315-9. PubMed ID: 627138
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An improvement in digoxin bioavailability. Studies with soft gelatin capsules containing a solution of digoxin.
    Alvisi V; Longhini C; Bagni B; Portaluppi F; Ruina M; Fersini C
    Arzneimittelforschung; 1979; 29(7):1047-50. PubMed ID: 582997
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Digoxin-prescribing. Mostly good news.
    Weintraub M; Karch FE; Morgan JP; Trabert N; Sorensen A; Becker LA; Lasagna L
    JAMA; 1979 Aug; 242(5):445-8. PubMed ID: 448961
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessment of bio(in)equivalence of deriphyllin-digoxin in human volunteers.
    Bansinath M; Ghosh SS; Shafiqa A; Shukla VK; Chopra KS; Mathur VS
    Int J Clin Pharmacol Ther Toxicol; 1986 Jan; 24(1):30-3. PubMed ID: 3957487
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Biologic availability of digoxin in soft gelatin capsules and in tablets].
    Merotti GC; Ghirardi P; Marzo A; Parenti MA
    Boll Soc Ital Biol Sper; 1974 Oct; 50(19):1612-4. PubMed ID: 4458749
    [No Abstract]   [Full Text] [Related]  

  • 48. Serum levels of digoxin administered in soft gelatin capsules and tablets and evaluated by both radioimmunoassay and enzyme immunoassay.
    Nicaise J; Molron D; Gandolfi C; Ghirardi P; Marzo A
    Farmaco Prat; 1981 Jul; 36(7):341-6. PubMed ID: 7023968
    [No Abstract]   [Full Text] [Related]  

  • 49. [Plasma digoxin during treatment with "new" Lanoxin].
    Falch D; Teien A; Odegaard AE
    Tidsskr Nor Laegeforen; 1973 Aug; 93(23):1610-1. PubMed ID: 4769482
    [No Abstract]   [Full Text] [Related]  

  • 50. Evaluation of digoxin capsules in outpatients.
    Rodgers EM; Dobbs SM; Kenyon WI; Poston JW
    Br Med J; 1977 Jul; 2(6081):234-5. PubMed ID: 884449
    [No Abstract]   [Full Text] [Related]  

  • 51. Influence of soft gelatin on digoxin absorption.
    O'Grady J; Johnson BF; Bye C; Sabey GA
    Br J Clin Pharmacol; 1978 May; 5(5):461-3. PubMed ID: 656286
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bioequivalence of single and multiple doses of venlafaxine extended-release tablets and capsules in the fasted and fed states: four open-label, randomized crossover trials in healthy volunteers.
    Wright CW; Aikman MS; Werts E; Seabolt J; Haeusler JM
    Clin Ther; 2009 Nov; 31(11):2722-34. PubMed ID: 20110014
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Bioavailability of digoxin in capsules and tablets and correlated indices of myocardial function in 9 heart disease patients].
    Astorri E; La Canna G; Bianchi G; Assanelli D; Lombardi F; Dei Cas L
    Boll Soc Ital Cardiol; 1978; 23(6):987-94. PubMed ID: 261884
    [No Abstract]   [Full Text] [Related]  

  • 54. Falsely high serum drug concentrations caused by blood samples from contaminated fingers.
    Roberts GW; Aldis JJ
    Ther Drug Monit; 1990 Nov; 12(6):558-61. PubMed ID: 2275002
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of jejunoileal bypass on the pharmacokinetics of digoxin in man.
    Marcus FI; Quinn EJ; Horton H; Jacobs S; Pippin S; Stafford M; Zukoski C
    Circulation; 1977 Mar; 55(3):537-41. PubMed ID: 837489
    [TBL] [Abstract][Full Text] [Related]  

  • 56. ["New" and "old" Lanoxin. Some Assessments based on digoxin measurements in controlled clinical trials].
    Falch D
    Tidsskr Nor Laegeforen; 1973 Aug; 93(23):1607-9. PubMed ID: 4588816
    [No Abstract]   [Full Text] [Related]  

  • 57. The influence of digoxin particle size on absorption of digoxin and the effect of propantheline and metoclopramide.
    Johnson BF; O'Grady J; Bye C
    Br J Clin Pharmacol; 1978 May; 5(5):465-7. PubMed ID: 656287
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [How should Lanoxin be used? Practical advice founded on pharmacokinetic investigations].
    Osnes JB
    Tidsskr Nor Laegeforen; 1973 Aug; 93(23):1614-5. PubMed ID: 4769483
    [No Abstract]   [Full Text] [Related]  

  • 59. Bioavailability and digoxin.
    N Z Med J; 1972 Sep; 76(484):203. PubMed ID: 4508750
    [No Abstract]   [Full Text] [Related]  

  • 60. Digoxin: use pattern in Estonia and bioavailability of the local market leader.
    Pähkla R; Irs A; Oselin K; Rootslane L
    J Clin Pharm Ther; 1999 Oct; 24(5):375-80. PubMed ID: 10583701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.